Novonesis sets post-merger pace, shares tracked against European biotech peers
22.06.2026 - 19:22:54 | ad-hoc-news.de
By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-22, 19:14.
Novonesis (DK0060336014) is still being priced by the market as investors digest the merger of enzyme specialists Novozymes and Chr. Hansen. The Danish group sits in the European biotech and specialty chemicals space alongside peers such as Novozymes’ former comparator DSM-Firmenich and diabetes leader Novo Nordisk on the OMX Copenhagen 25, with recent commentary highlighting a solid first quarter and full-year 2026 targets described as on track, according to MarketScreener.
What recent reports highlight
On 8 May 2026, MarketScreener summarized broker reactions under the headline "Novonesis: Solid Q1; FY26 on track", pointing to a broadly constructive view on integration progress and growth expectations for the combined entity. MarketScreener notes on Novonesis Q1 and FY26 In that piece, analysts emphasized organic growth leverage in food, beverage and bioenergy enzymes, while flagging that cost synergies from the merger are scheduled to ramp gradually through 2026.
The report also underlined that Novonesis management reaffirmed its full-year 2026 guidance ranges after the first quarter, which brokers interpreted as a sign of confidence in underlying demand trends. According to the same summary, the newly combined group is expected to deliver mid-single-digit to high-single-digit organic revenue growth, with margin improvement supported by synergy capture and portfolio rationalization.
Position in the European peer group
Within the European landscape, Novonesis is often compared with DSM-Firmenich in Netherlands-listed specialty nutrition and with pharma-heavyweights such as Novo Nordisk on the OMX Copenhagen 25, which has been a key driver of Nordic biotech valuations. Finanzen.net coverage of Novo Nordisk on OMX Copenhagen 25 While business models differ, these peers frame investor expectations on growth, research spending and profitability in the broader Nordic life-sciences cluster.
Exchange data compiled by Finanzen100 show the Novonesis B shares with ISIN DK0060336014 trading in euros on German platforms under the symbol NZM2 and WKN A1JP9Y, providing an additional point of access for continental investors beyond Copenhagen. Finanzen100 profile for Novonesis B In that context, sector watchers look at how Novonesis’ valuation multiples compare to European biotechnology and specialty chemicals benchmarks when assessing the combined group’s long-term potential.
All news and analysis on the Novonesis shares
Further background, price data and corporate disclosures on Novonesis can be found in the dedicated topic area and on the company's investor relations pages.
How Novonesis makes its money
Novonesis generates revenue by developing and producing industrial enzymes and microbial solutions that customers use to optimize processes in sectors such as food, beverages, household care and bioenergy. The former Novozymes portfolio includes products like baking enzymes that help bread maintain softness and freshness, as well as enzymes for detergents that enable effective cleaning at lower temperatures and reduced water use, according to company materials. Novonesis business description and application areas Through the merger with Chr. Hansen, the group has expanded its microbial and probiotic offerings, targeting both consumer health products and agricultural productivity solutions.
Where the shares trade today
The Novonesis B shares (DK0060336014) most recently traded on German platforms such as Tradegate at around 52.44 euros on 2026-06-22, 17:45, in line with the level indicated by Finanzen100 for the NZM2 listing.
Key data on the Novonesis shares
- Company: Novonesis A/S
- ISIN: DK0060336014
- WKN: A1JP9Y
- Ticker: NZM2
- Trading venue: Tradegate (Germany)
- Price (as of 2026-06-22, 17:45): 52.44 EUR
- Market cap: not specified in German quote sources checked on 2026-06-22
- Sector / industry: Biotechnology / Specialty chemicals (industrial enzymes and microbial solutions)
- Index membership: not disclosed in the German trading snapshot; the company is part of the Copenhagen-listed Nordic life sciences universe
- Next earnings date: not officially scheduled on the investor relations calendar checked on 2026-06-22
This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial service. All data have been carefully researched but carry no guarantee.
